Vesigen Therapeutics

Vesigen Therapeutics

  • Founded: 2019
  • Location: Cambridge, MA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: Neurological diseases
  • Drug types: NEU, OPH, IMM
  • Lead product: Undisclosed
  • Product link:
  • Funding: $28.5M A Jul 2020

job board

Short description:

Fusogenic extracellular vesicle delivery technology

Drug notes:

Undisclosed programs RD ocular conditions, immune modulation

Long description:

Vesigen Therapeutics is a developing exosome-based therapies for the treatment of a variety of diseases. Exosomes are small vesicles that are released by cells and can deliver cargo to other cells. Vesigen’s exosome engineering platform allows the company to engineer exosomes to deliver specific therapeutic cargo, such as siRNA, mRNA, or proteins. Vesigen is developing exosome-based therapies for a variety of diseases, including cancer, neurodegenerative diseases, and inflammatory diseases. The company's lead product candidate, VSG-101, is an exosome-based therapy for the treatment of glioblastoma multiforme (GBM), a type of brain cancer.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy